Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.

Shin, Sol-Bi; Woo, Sang-Uk; Yim, Hyungshin

Shin, Sol-Bi; Woo, Sang-Uk; Yim, Hyungshin.

Affiliation

Shin SB; Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Woo SU; Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Yim H; Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do 15588, Korea.

Ther Adv Med Oncol ; 11: 1758835919846375, 2019.

Article in En | MEDLINE | ID: mdl-31156720

Key words

Plk1; androgen receptor; paclitaxel; resistance

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies Language: En Journal: Ther Adv Med Oncol Year: 2019 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google